Core Viewpoint - The company, Xinmai Medical, has announced the use of part of its temporarily idle raised funds for cash management, ensuring that this will not affect its investment plans and will support operational liquidity and project funding needs [1]. Group 1: Stock Performance - As of January 19, 2026, Xinmai Medical's stock closed at 96.73 yuan, down 1.28% from the previous trading day, with a total market capitalization of 11.923 billion yuan [1]. - The stock opened at 97.93 yuan, reached a high of 98.5 yuan, and a low of 96.66 yuan, with a trading volume of 1.41 billion yuan and a turnover rate of 1.17% [1]. Group 2: Fund Management Announcement - The company held its 12th meeting of the 3rd Board of Directors on January 19, 2026, where it approved the use of up to 1 billion yuan of temporarily idle raised funds for cash management [1]. - The investment will focus on high safety and liquidity products, including structured deposits, notice deposits, time deposits, large certificates of deposit, and income certificates [1]. - The usage period for these funds is within 12 months from the date of board approval, and the funds can be rolled over [1]. - The company has committed that this action will not impact the normal execution of its fundraising investment plans, and any earnings will be used to cover funding shortfalls for investment projects and daily operational liquidity [1].

Core Viewpoint - The company has approved the use of idle raised funds for cash management, emphasizing that this will not affect the progress of investment projects or normal operations [1] Group 1 - The company will use up to 380 million yuan of temporarily idle raised funds for cash management [1] - The approved cash management will involve high-security, liquid financial products, structured deposits, or fixed-term deposits [1] - The funds can be rolled over within a 12-month period from the date of board approval [1]

Core Viewpoint - Dongpeng Beverage plans to utilize part of its idle raised funds for cash management, specifically through structured deposits, to enhance the efficiency of fund usage and increase company revenue while ensuring that it does not affect the normal investment plans of the raised funds [2][4][11]. Group 1: Cash Management Overview - The entrusted party for cash management is China Merchants Bank Co., Ltd. [2] - The total amount for cash management is 70 million yuan [2]. - The type of cash management product is structured deposits with a duration of 70 days [2][8]. - The company has authorized the use of up to 100 million yuan for cash management, ensuring that daily operational funding needs and fund safety are prioritized [2][13]. Group 2: Previous Financial Management - The previous structured deposit purchased on October 15, 2025, matured on January 15, 2026, with the principal and earnings fully returned to the raised funds account [4]. - The funds used for this investment are from the company's initial public offering, which raised a total of 1.851 billion yuan, netting 1.732 billion yuan after expenses [5]. Group 3: Risk Control Measures - The company has established a comprehensive internal control system for cash management, including risk assessment and decision-making processes to ensure the safety of funds [6][9]. - The company will select low-risk investment products and monitor market conditions to mitigate potential risks [9][10]. - Independent directors and the sponsor have the authority to supervise the use of raised funds, ensuring compliance with regulations [7][9]. Group 4: Impact on Company - The cash management initiative is not expected to significantly impact the company's main business, financial status, operating results, or cash flow [11]. - The company will report the specifics of the cash management activities in accordance with relevant regulations [10].

Core Viewpoint - The company is utilizing part of its idle raised funds for cash management, achieving a redemption of RMB 157.488 million with a return of RMB 9.0115 million, while continuing to manage cash with an additional investment of RMB 158.4 million [2][4]. Group 1: Cash Management Redemption - The company redeemed RMB 157.488 million of idle raised funds from cash management products, earning RMB 9.0115 million in returns [2]. - The board approved the use of up to RMB 5 billion of idle raised funds for cash management, focusing on high-security, liquid, and capital-preserving investment products [3]. Group 2: Ongoing Cash Management - As of the announcement date, the company has a total of RMB 320 million in unredeemed idle raised funds allocated for cash management, which is within the board's authorized limit [4]. - The company continues to invest in cash management products to enhance fund utilization efficiency and achieve investment returns [8]. Group 3: Risk Management and Control - The company will analyze and monitor the investment products and take necessary measures to control investment risks based on economic conditions [7]. - The finance department will maintain records of cash management activities and ensure proper accounting practices [7]. Group 4: Impact on Operations - The use of idle raised funds for cash management will not affect the company's daily operations or the normal progress of fundraising investment projects, ensuring the safety of the principal [8].

Core Viewpoint - Jiangsu Yahon Pharmaceutical Technology Co., Ltd. plans to utilize part of its temporarily idle raised funds for cash management, aiming to enhance fund efficiency while ensuring the safety of the raised funds and the implementation of investment projects [1][2]. Cash Management Overview - The company intends to use a maximum of RMB 1.2 billion (including the amount) of temporarily idle raised funds for cash management, with a validity period of 12 months from the date of the board's approval [2][8]. - The cash management aims to increase returns for the company and its shareholders while not affecting the normal operation of the fundraising investment projects [2][12]. Investment Details - The investment will focus on high-security, high-liquidity financial products sold by qualified financial institutions, including agreement deposits, time deposits, notice deposits, large certificates of deposit, structured deposits, and income certificates [4][8]. - The company will not use these funds for securities investment purposes [4]. Implementation and Oversight - The board has authorized the chairman to make investment decisions and sign relevant contracts within the approved limits and timeframe, with the finance department responsible for implementation [5][8]. - The company will adhere to strict regulatory requirements and maintain a separation of decision-making, execution, and supervision functions to ensure fund safety [10]. Impact on the Company - The use of temporarily idle raised funds for cash management is expected to improve fund efficiency and provide good investment returns for the company and its shareholders, without affecting daily cash flow needs or the normal operation of fundraising projects [12]. Opinions from Intermediaries - The sponsor, CITIC Securities Co., Ltd., has reviewed the cash management plan and found it compliant with relevant laws and regulations, expressing no objections to the company's decision [12].

Core Viewpoint - The company has approved a proposal to use part of the idle funds raised from convertible bonds for cash management, specifically investing in low-risk financial products [1] Group 1: Financial Management - The company plans to utilize up to 150 million yuan of idle funds for cash management [1] - The investment will focus on safe, principal-protected products such as structured deposits and large certificates of deposit [1] - The authorization for this cash management initiative is valid for 12 months from the date of approval by the shareholders' meeting [1] Group 2: Impact on Operations - This cash management decision will not affect the progress of the fundraising investment projects or the company's normal production and operations [1]

Core Viewpoint - The company, Yahuang Pharmaceutical, has announced the approval of a proposal to use up to 1.2 billion yuan of temporarily idle raised funds for cash management, focusing on safe and liquid investment products [1] Group 1: Financial Management - The board of directors approved the use of idle funds for cash management, with a maximum limit of 1.2 billion yuan [1] - The investment products will be purchased from financial institutions that offer high safety, good liquidity, and capital protection agreements [1] - The usage period for these funds is valid for 12 months from the date of board approval, and the funds can be rolled over within the approved limit [1] Group 2: Impact on Operations - This decision will not affect the progress of the fundraising investment projects or the normal production and operation of the company [1]

Group 1 - The company Baixinglong announced the investment of 15 million yuan of idle raised funds into a financial product from Industrial Bank's Luohu branch, specifically the "Industrial Bank Wealth Management · Daily Xin Stable Income Fixed Income Open Corporate Wealth Management Product 25G5745C" [2] - The financial product allows for redemption at any time and is expected to yield an annualized return of 1.5% to 1.9% [2] - As of January 15, 2026, the remaining balance of the raised funds in this financial product is 15 million yuan, which does not exceed the authorized limit of 18 million yuan [2]

Core Viewpoint - The company has announced the approval to utilize part of its idle raised funds for cash management, indicating a strategic move to enhance liquidity and financial management [1] Group 1: Financial Management - The company will use up to 190 million yuan of idle raised funds for cash management [1] - The investment direction includes purchasing low-risk, high-security, and liquid principal-protected financial products, such as structured deposits and large certificates of deposit [1] - The usage period for these funds is effective within 12 months, allowing for rolling use within the approved limit [1] Group 2: Impact on Operations - The company emphasizes that this decision will not affect the progress of the investment projects funded by the raised capital or the normal production and operations of the company [1]

Core Viewpoint - The company plans to utilize up to RMB 240 million of its idle raised funds for cash management, focusing on low-risk investment products to enhance fund efficiency and generate returns for shareholders [1][4]. Group 1: Opening of Special Settlement Account - To improve the efficiency of raised funds, the company opened a special settlement account for cash management products on January 13, 2026 [2]. - The account will exclusively handle temporarily idle raised funds and will not be used for non-raised funds or other purposes [2]. Group 2: Risk Control Measures - The company will adhere to relevant regulations and internal policies to manage cash effectively and ensure fund safety [3]. - Independent directors and the audit committee will supervise fund usage, with the option to hire professional institutions for audits if necessary [3]. Group 3: Impact on the Company - The cash management of idle raised funds will not affect the normal use of funds for project construction or daily operations [4]. - This strategy aims to enhance fund efficiency and provide better investment returns for the company and its shareholders [4].